kynurenic acid has been researched along with Sepsis in 4 studies
Kynurenic Acid: A broad-spectrum excitatory amino acid antagonist used as a research tool.
kynurenic acid : A quinolinemonocarboxylic acid that is quinoline-2-carboxylic acid substituted by a hydroxy group at C-4.
Sepsis: Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirty-six patients with severe sepsis/septic shock and sepsis-associated immunosuppression (assessed using monocytic human leukocyte antigen-DR (mHLA-DR) expression) were assessed in a controlled trial of GM-CSF or placebo treatment for 8 days." | 6.75 | Treatment with granulocyte-macrophage colony-stimulating factor is associated with reduced indoleamine 2,3-dioxygenase activity and kynurenine pathway catabolites in patients with severe sepsis and septic shock. ( Fotopoulou, C; Fusch, G; Hammoud, B; Hasper, D; Meisel, C; Pschowski, R; Reinke, P; Schefold, JC; Schütt, C; Volk, HD; Von Haehling, S; Zeden, JP, 2010) |
| "Sepsis was characterized by significantly elevated ROFA scores, while the increased BBB permeability and plasma S100B levels demonstrated brain damage." | 5.62 | Kynurenic Acid and Its Synthetic Derivatives Protect Against Sepsis-Associated Neutrophil Activation and Brain Mitochondrial Dysfunction in Rats. ( Boros, M; Czakó, BL; Dookhun, D; Fülöp, F; Gál, KG; Glenz, RJ; Gulácsi, L; Juhász, L; Kaszaki, J; Lőrinczi, B; Nászai, A; Poles, MZ; Rutai, A; Szabó, A; Szatmári, I; Tallósy, SP; Vécsei, L, 2021) |
| "Thirty-six patients with severe sepsis/septic shock and sepsis-associated immunosuppression (assessed using monocytic human leukocyte antigen-DR (mHLA-DR) expression) were assessed in a controlled trial of GM-CSF or placebo treatment for 8 days." | 2.75 | Treatment with granulocyte-macrophage colony-stimulating factor is associated with reduced indoleamine 2,3-dioxygenase activity and kynurenine pathway catabolites in patients with severe sepsis and septic shock. ( Fotopoulou, C; Fusch, G; Hammoud, B; Hasper, D; Meisel, C; Pschowski, R; Reinke, P; Schefold, JC; Schütt, C; Volk, HD; Von Haehling, S; Zeden, JP, 2010) |
| "Kynurenic acid is a common differential metabolite that could be used as a candidate for both diagnosis and prognosis for septic patients with cardiac dysfunction." | 1.91 | Untargeted metabolomic profiling of sepsis-induced cardiac dysfunction. ( Cao, Y; Fang, C; Han, X; Huang, J; Jing, Y; Liu, Z; Ma, W; Pei, Y; Xiao, W, 2023) |
| "Sepsis was characterized by significantly elevated ROFA scores, while the increased BBB permeability and plasma S100B levels demonstrated brain damage." | 1.62 | Kynurenic Acid and Its Synthetic Derivatives Protect Against Sepsis-Associated Neutrophil Activation and Brain Mitochondrial Dysfunction in Rats. ( Boros, M; Czakó, BL; Dookhun, D; Fülöp, F; Gál, KG; Glenz, RJ; Gulácsi, L; Juhász, L; Kaszaki, J; Lőrinczi, B; Nászai, A; Poles, MZ; Rutai, A; Szabó, A; Szatmári, I; Tallósy, SP; Vécsei, L, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Poles, MZ | 1 |
| Nászai, A | 1 |
| Gulácsi, L | 1 |
| Czakó, BL | 1 |
| Gál, KG | 1 |
| Glenz, RJ | 1 |
| Dookhun, D | 1 |
| Rutai, A | 1 |
| Tallósy, SP | 1 |
| Szabó, A | 1 |
| Lőrinczi, B | 1 |
| Szatmári, I | 1 |
| Fülöp, F | 1 |
| Vécsei, L | 1 |
| Boros, M | 1 |
| Juhász, L | 1 |
| Kaszaki, J | 1 |
| Cao, Y | 1 |
| Liu, Z | 1 |
| Ma, W | 1 |
| Fang, C | 1 |
| Pei, Y | 1 |
| Jing, Y | 1 |
| Huang, J | 1 |
| Han, X | 1 |
| Xiao, W | 1 |
| Schefold, JC | 1 |
| Zeden, JP | 1 |
| Pschowski, R | 1 |
| Hammoud, B | 1 |
| Fotopoulou, C | 1 |
| Hasper, D | 1 |
| Fusch, G | 1 |
| Von Haehling, S | 1 |
| Volk, HD | 1 |
| Meisel, C | 1 |
| Schütt, C | 1 |
| Reinke, P | 1 |
| Heyes, MP | 1 |
| Lackner, A | 1 |
1 trial available for kynurenic acid and Sepsis
| Article | Year |
|---|---|
Treatment with granulocyte-macrophage colony-stimulating factor is associated with reduced indoleamine 2,3-dioxygenase activity and kynurenine pathway catabolites in patients with severe sepsis and septic shock.
Topics: Aged; Calcitonin; Calcitonin Gene-Related Peptide; Granulocyte-Macrophage Colony-Stimulating Factor; | 2010 |
3 other studies available for kynurenic acid and Sepsis
| Article | Year |
|---|---|
Kynurenic Acid and Its Synthetic Derivatives Protect Against Sepsis-Associated Neutrophil Activation and Brain Mitochondrial Dysfunction in Rats.
Topics: Animals; Blood-Brain Barrier; Disease Models, Animal; Kynurenic Acid; Male; Mitochondria; Neuroprote | 2021 |
Untargeted metabolomic profiling of sepsis-induced cardiac dysfunction.
Topics: Chromatography, Liquid; Discriminant Analysis; Humans; Kynurenic Acid; Metabolomics; Sepsis | 2023 |
Increased cerebrospinal fluid quinolinic acid, kynurenic acid, and L-kynurenine in acute septicemia.
Topics: Acute Disease; Animals; Female; Kynurenic Acid; Kynurenine; Macaca mulatta; Male; Pyridines; Quinoli | 1990 |